VRCA vs. ESPR, INMB, INBX, ACTU, IPHA, CYBN, LFVN, AARD, NBTX, and MOLN
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Esperion Therapeutics (ESPR), INmune Bio (INMB), Inhibrx (INBX), Actuate Therapeutics (ACTU), Innate Pharma (IPHA), Cybin (CYBN), LifeVantage (LFVN), Aardvark Therapeutics (AARD), Nanobiotix (NBTX), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry.
Verrica Pharmaceuticals vs.
Esperion Therapeutics (NASDAQ:ESPR) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.
Verrica Pharmaceuticals has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Esperion Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500.
Esperion Therapeutics currently has a consensus target price of $6.42, indicating a potential upside of 542.05%. Verrica Pharmaceuticals has a consensus target price of $9.50, indicating a potential upside of 1,946.53%. Given Verrica Pharmaceuticals' higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Esperion Therapeutics.
In the previous week, Esperion Therapeutics had 12 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 14 mentions for Esperion Therapeutics and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Esperion Therapeutics' score of 0.51 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.
47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by company insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Esperion Therapeutics has a net margin of -29.37% compared to Verrica Pharmaceuticals' net margin of -625.06%. Esperion Therapeutics' return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.
Esperion Therapeutics received 463 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. Likewise, 70.23% of users gave Esperion Therapeutics an outperform vote while only 63.26% of users gave Verrica Pharmaceuticals an outperform vote.
Summary
Esperion Therapeutics beats Verrica Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRCA) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy VRCA Stock Free VRCA Stock Alerts